The project will develop advanced stem cell products ready for use in clinical trials in Type 1 Diabetes. The project will develop a manufacturing pipeline for stem cell-based products to treat patients with Type 1 Diabetes. In Type 1 Diabetes a patient’s immune system destroys the beta cells within the islets of Langerhans in the pancreas making a patient dependent on life-long delivery of insulin.
Based on in-house methods, ISLET will deliver a product composed of clusters of insulin-producing beta cells, derived from human pluripotent stem cells, ready to be used in phase 1 clinical trials.
- Data di pubblicazione
- 13 dicembre 2019
- Direzione generale della Ricerca e dell’innovazione